Particle.news

FDA Requires NAION Warning on GLP‑1 Drugs

Pooled trial data showed a small absolute rise in a rare optic‑nerve stroke, prompting regulators to require the label change.

Overview

  • The FDA announced on November 9, 2026 that manufacturers must add a warning about non‑arteritic anterior ischemic optic neuropathy (NAION), a sudden, often permanent, painless loss of vision caused by reduced blood flow to the optic nerve.
  • The agency pooled 126 randomized trials and found NAION rates of 6.4 versus 3.8 cases per 100,000 person‑years for people on GLP‑1 drugs compared with placebo or other glucose‑lowering drugs, a small absolute increase in risk.
  • Clinical experts say the evidence shows an association but not proven causation and advise patients not to stop GLP‑1 therapy without consulting their clinician because the drugs provide substantial metabolic and cardiovascular benefits.
  • Key unknowns remain about why NAION may occur, whether risk differs by specific GLP‑1 agent or treatment duration, and regulators and researchers have called for longer‑term studies and targeted safety surveillance.
  • Patients should watch for sudden vision changes and seek immediate eye care, clinicians can use routine diabetic eye exams to check optic‑nerve features, and the label change may affect postmarket monitoring, research priorities and related legal cases.